膿毒癥是一種由細(xì)菌等病原微生物侵入機(jī)體引起的全身炎癥反應(yīng)綜合征,常伴有器官功能障礙、組織灌注不良、低血壓甚至膿毒性休克。血管功能障礙與膿毒癥之間存在明確的關(guān)系。血管生成素/酪氨酸蛋白激酶-2(Ang/Tie2)通路可以作為控制炎癥、防止血管滲漏藥物研發(fā)的重要靶點(diǎn),為膿毒癥治療提供新的可能性。靶向Ang/Tie2通路的膿毒癥治療藥物有重組人Ang1腺病毒、Ang1類似物、Ang2抑制劑、重組人Ang2和Tie2激動(dòng)劑?？偨Y(jié)了靶向Ang/Tie2通路的膿毒癥治療藥物的研究進(jìn)展,以期為膿毒癥治療藥物的開發(fā)提供思路。

Sepsis is a systemic inflammatory response syndrome caused by the invasion of pathogenic microorganisms such as bacteria into the body, often accompanied by organ dysfunction, poor tissue perfusion, hypotension, and even septic shock. There is a clear relationship between vascular dysfunction and sepsis. The angiopoietin/tyrosine protein kinase-2 (Ang/Tie2) pathway can serve as an important target for the development of drugs to control inflammation and prevent vascular leakage, providing new possibilities for the treatment of sepsis. The therapeutic drugs targeting the Ang/Tie2 pathway for sepsis include recombinant human Ang1 adenovirus, Ang1 analogues, Ang2 inhibitors, recombinant human Ang2, and Tie2 agonists. This article summarizes the research progress of drugs for sepsis targeting the Ang/Tie2 pathway, aiming to provide ideas for the development of sepsis treatment drugs.

R976

國家自然科學(xué)基金面上項(xiàng)目（81973672）；山西省“四個(gè)一批”科技興醫(yī)創(chuàng)新計(jì)劃（2020SYS06）；山西省基礎(chǔ)研究計(jì)劃（202203021221291）；山西省科技創(chuàng)新人才團(tuán)隊(duì)（202204051001032）